1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Anthera Pharmaceuticals‚ Inc. - Product Pipeline Review - 2013

Anthera Pharmaceuticals‚ Inc. - Product Pipeline Review - 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 27 pages

Anthera Pharmaceuticals‚ Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Anthera Pharmaceuticals‚ Inc. - Product Pipeline Review - 2013” provides data on the Anthera Pharmaceuticals‚ Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Anthera Pharmaceuticals‚ Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Anthera Pharmaceuticals‚ Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Anthera Pharmaceuticals‚ Inc. - Brief Anthera Pharmaceuticals‚ Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Anthera Pharmaceuticals‚ Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Anthera Pharmaceuticals‚ Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Anthera Pharmaceuticals‚ Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Anthera Pharmaceuticals‚ Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Anthera Pharmaceuticals‚ Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Anthera Pharmaceuticals‚ Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Anthera Pharmaceuticals‚ Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Anthera Pharmaceuticals‚ Inc. and identify potential opportunities in those areas.

Table Of Contents

Anthera Pharmaceuticals‚ Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Anthera Pharmaceuticals‚ Inc. Snapshot 4
Anthera Pharmaceuticals‚ Inc. Overview 4
Key Information 4
Key Facts 4
Anthera Pharmaceuticals‚ Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Anthera Pharmaceuticals‚ Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Anthera Pharmaceuticals‚ Inc. - Pipeline Products Glance 9
Anthera Pharmaceuticals‚ Inc. - Late Stage Pipeline 9
Phase III Products/Combination Treatment Modalities 9
Anthera Pharmaceuticals‚ Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Anthera Pharmaceuticals‚ Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Anthera Pharmaceuticals‚ Inc. - Drug Profiles 12
A-003 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
A-101 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
blisibimod 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Anthera Pharmaceuticals‚ Inc. - Pipeline Analysis 15
Anthera Pharmaceuticals‚ Inc. - Pipeline Products by Therapeutic Class 15
Anthera Pharmaceuticals‚ Inc. - Pipeline Products By Target 16
Anthera Pharmaceuticals‚ Inc. - Pipeline Products by Route of Administration 17
Anthera Pharmaceuticals‚ Inc. - Pipeline Products By Mechanism of Action 18
Anthera Pharmaceuticals‚ Inc. - Recent Pipeline Updates 19
Anthera Pharmaceuticals‚ Inc. - Dormant Projects 23
Anthera Pharmaceuticals‚ Inc. - Discontinued Pipeline Products 24
Discontinued Pipeline Product Profiles 24
varespladib methyl 24
varespladib sodium 24
Anthera Pharmaceuticals‚ Inc. - Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27



List of Tables

Anthera Pharmaceuticals‚ Inc., Key Information 4
Anthera Pharmaceuticals‚ Inc., Key Facts 4
Anthera Pharmaceuticals‚ Inc. - Pipeline by Indication, 2013 6
Anthera Pharmaceuticals‚ Inc. - Pipeline by Stage of Development, 2013 7
Anthera Pharmaceuticals‚ Inc. - Monotherapy Products in Pipeline, 2013 8
Anthera Pharmaceuticals‚ Inc. - Phase III, 2013 9
Anthera Pharmaceuticals‚ Inc. - Phase II, 2013 10
Anthera Pharmaceuticals‚ Inc. - Preclinical, 2013 11
Anthera Pharmaceuticals‚ Inc. - Pipeline By Therapeutic Class, 2013 15
Anthera Pharmaceuticals‚ Inc. - Pipeline By Target, 2013 16
Anthera Pharmaceuticals‚ Inc. - Pipeline By Route of Administration, 2013 17
Anthera Pharmaceuticals‚ Inc. - Pipeline Products By Mechanism of Action, 2013 18
Anthera Pharmaceuticals‚ Inc. - Recent Pipeline Updates, 2013 19
Anthera Pharmaceuticals‚ Inc. - Dormant Developmental Projects,2013 23
Anthera Pharmaceuticals‚ Inc. - Discontinued Pipeline Products, 2013 24



List of Figures

Anthera Pharmaceuticals‚ Inc. - Pipeline by Indication, 2013 6
Anthera Pharmaceuticals‚ Inc. - Pipeline by Stage of Development, 2013 7
Anthera Pharmaceuticals‚ Inc. - Monotherapy Products in Pipeline, 2013 8
Anthera Pharmaceuticals‚ Inc. - Pipeline By Therapeutic Class, 2013 15
Anthera Pharmaceuticals‚ Inc. - Pipeline By Route of Administration, 2013 17
Anthera Pharmaceuticals‚ Inc. - Pipeline Products By Mechanism of Action, 2013 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.